All Comments by John Trojanowski

  1. Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease.
  2. Chronic traumatic encephalopathy in a national football league player: part II.
  3. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
  4. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
  5. CSF Biomarkers—Maybe You Can See the Forest for the Trees
  6. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease.
  7. 100 years and counting: prospects for defeating Alzheimer's disease.
  8. A century of Alzheimer's disease.
  9. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
  10. A peptide zipcode sufficient for anterograde transport within amyloid precursor protein.
  11. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles.
  12. Double Paper Alert—A Function for BACE, a Basis for Amyloid
  13. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.
  14. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.
  15. Dangerous Liaisons—Tau and Aβ, Together at Last?